Business UpdateJun 4, 2026, 09:02 AM
Lipocine to Host KOL Event on LPCN 1154 for Postpartum Depression
AI Summary
Lipocine Inc. announced it will host a virtual Key Opinion Leader (KOL) event on Friday, June 12, 2026, to discuss unmet needs in postpartum depression (PPD) and the clinical profile of LPCN 1154 (BRLIZIO"). The event will feature leading physicians and Lipocine management, reviewing the current PPD treatment landscape, persistent gaps in care, and Phase 3 topline results for LPCN 1154, an investigational oral brexanolone. The discussion will also cover the potential positioning of LPCN 1154 within PPD and broader depression treatment paradigms.
Key Highlights
- Lipocine to host virtual KOL event on June 12, 2026, at 11:00 AM ET.
- Event to highlight unmet needs in postpartum depression (PPD) and LPCN 1154.
- LPCN 1154 (BRLIZIO") is an investigational oral brexanolone for PPD.
- Phase 3 trial showed clinically meaningful and statistically significant efficacy.
- LPCN 1154 was well tolerated with no treatment-related serious adverse events.
- PPD affects approximately 1 in 5 women, with 600,000 diagnosed annually in the US.
- Suicide is a leading cause of maternal mortality in the first year postpartum.
Price Impact
More from LPCN